Osteopore (ASX:OSX), a global regenerative medicine company founded in Singapore and listed in Australia, is delighted to announce that it has secured approval from the Hainan Medical Product Administration, for the use of the Company’s neurosurgery products at Ruijin Hospital in China’s Hainan Boao Lecheng International Medical Tourism Pilot Zone.
This approval is a key milestone in the Company’s expansion into China and the delivery of one of Osteopore’s mature neurosurgical products, Osteoplug. Ruijin Hospital is affiliated with Shanghai Jiao Tong University School of Medicine, which is frequently ranked #1 among medical schools in China, while being ranked #62 globally by the US News & World Report.
The Hainan Boao Lecheng Pilot Zone was launched to support the Healthy China 2030 plan. By 2025, the Pilot Zone is expected to draw more than 2 million people seeking medical treatment – including 0.5 million people who could have chosen overseas medical services. The Company can also collect real-world clinical data in Hainan to provide supplementary clinical data for an upcoming submission to the National Medical Products Administration (NMPA) – which could potentially expedite registration in mainland China.
